Directorate of Infection, Guy's and St Thomas' National Health Service Foundation Trust, London, UK.
Clin Infect Dis. 2010 Jan 15;50(2):210-7. doi: 10.1086/648717.
Surface-active antiseptics, such as chlorhexidine, are increasingly being used as part of intervention programs to prevent methicillin-resistant Staphylococcus aureus (MRSA) transmission, despite limited evidence and potential for resistance. We report on the effect of an antiseptic protocol on acquisition of both endemic MRSA and an outbreak strain of MRSA sequence type 239 (designated TW).
Interrupted time-series data on MRSA acquisitions in two 15-bed intensive care units were analyzed using segmented regression models to estimate the effects of sequential introduction of an educational campaign, cohorting, and a chlorhexidine-based antiseptic protocol on transmission of TW and non-TW MRSA strains. Representative TW and non-TW MRSA strains were assessed for carriage of qacA/B genes and antiseptic susceptibility.
The antiseptic protocol was associated with a highly significant, immediate 70% reduction in acquisition of non-TW MRSA strains (estimated model-averaged incidence rate ratio, 0.3; 95% confidence interval, 0.19-0.47) and an increase in acquisition of TW MRSA strains (estimated model-averaged incidence rate ratio, 3.85; 95% confidence interval, 0.80-18.59). There was only weak evidence of an effect of other interventions on MRSA transmission. All TW MRSA strains (21 of 21 isolates) and <5% (1 of 21 isolates) of non-TW MRSA strains tested carried the chlorhexidine resistance loci qacA/B. In vitro chlorhexidine minimum bactericidal concentrations of TW strains were 3-fold higher than those of non-TW MRSA strains, and in vivo, only patients with non-TW MRSA demonstrated a reduction in the number of colonization sites in response to chlorhexidine treatment.
A chlorhexidine-based surface antiseptic protocol can interrupt transmission of MRSA in the intensive care unit, but strains carrying qacA/B genes may be unaffected or potentially spread more rapidly.
尽管证据有限且存在耐药的可能性,表面活性剂型消毒剂(如洗必泰)仍被越来越多地用于预防耐甲氧西林金黄色葡萄球菌(MRSA)传播的干预措施中。我们报告了一种消毒剂方案对地方性 MRSA 和暴发株 MRSA 序列型 239(命名为 TW)的获得效果。
使用分段回归模型分析了两个 15 床重症监护病房的 MRSA 获得的中断时间序列数据,以估计连续引入教育运动、队列和基于洗必泰的消毒剂方案对 TW 和非 TW MRSA 菌株传播的影响。评估了代表性的 TW 和非 TW MRSA 菌株对 qacA/B 基因的携带情况和消毒剂的耐药性。
消毒剂方案与非 TW MRSA 菌株获得的显著、直接的 70%降低相关(估计模型平均发病率比,0.3;95%置信区间,0.19-0.47),并且 TW MRSA 菌株的获得增加(估计模型平均发病率比,3.85;95%置信区间,0.80-18.59)。其他干预措施对 MRSA 传播的影响只有微弱的证据。所有 TW MRSA 菌株(21 株分离株中的 21 株)和<5%(21 株非 TW MRSA 分离株中的 1 株)携带洗必泰耐药基因座 qacA/B。TW 菌株的洗必泰最低杀菌浓度比非 TW MRSA 菌株高 3 倍,而在体内,只有非 TW MRSA 的患者在接受洗必泰治疗后,其定植部位的数量减少。
基于洗必泰的表面消毒剂方案可以中断重症监护病房中 MRSA 的传播,但携带 qacA/B 基因的菌株可能不受影响或传播速度可能更快。